Ipsen's billion-dollar drug Somatoline is maintaining strong sales despite facing generic competition since 2021. The drug is extremely difficult to manufacture, which has prevented generic players from ramping up production. This "manufacturing moat" serves as a powerful, often overlooked, defense against revenue erosion after a patent cliff.

Adderall's success proves a core chemical patent isn't essential for market dominance. A strong brand that becomes synonymous with a condition, combined with secondary patents on novel delivery mechanisms (like Adderall XR's capsule), can create a durable, highly profitable business moat.

Instead of competing directly with an established drug, companies can target a non-overlapping, genetically defined patient population. Idea Biosciences' drug for uveal melanoma is for HLA A2-negative patients, while the approved drug KimTrac is for HLA A2-positive patients. This strategy allows for market entry without a head-to-head battle.

By succeeding in a difficult head-to-head superiority trial against a market leader—a feat no competitor has achieved—Ocular believes it has entered a "separate orbit." The CEO argues the high bar of the trial will deter any other company from attempting a similar study, thus protecting their market position for decades without direct competition on this claim.

While patents are important, a pharmaceutical giant's most durable competitive advantage is its ability to navigate complex global regulatory systems. This 'regulatory know-how' is a massive barrier to entry that startups cannot easily replicate, forcing them into acquisition by incumbents.

Arcus's strategy isn't to find novel targets, but to leverage its small-molecule expertise on validated targets that are difficult to drug. This de-risks the biology and creates a competitive moat based on technical execution, allowing them to develop a clearly better molecule against incumbents like Merck.

Wave Life Sciences' differentiation lies in advanced chemistry, including stereochemistry control, that results in a more durable knockdown of the target gene. This translates into a powerful competitive advantage: an infrequent dosing schedule (once or twice yearly) that dramatically improves patient convenience compared to weekly GLP-1 injections.

In therapeutic areas with no existing treatments, the first company to market can define the entire commercial landscape. By building the physician call points and delivery infrastructure from scratch, as Sarepta did for DMD, a biotech like NervGen can create a significant and lasting competitive advantage.

A key part of Eli Lilly's R&D strategy is tackling large-scale health problems that currently have no treatments and therefore represent a 'zero-dollar market.' This blue-ocean strategy contrasts with competitors who focus on areas with established payment pathways.